FGF19 and metabolic dysfunction-associated steatohepatitis: NGM282 is an engineered variant of human FGF19 that was found to retain the metabolic but not the tumorigenic effect of FGF-19 in preclinical models, and for this reason, it has been studied for the treatment of NASH.